<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0005124</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-16-01154</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Cholera vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Cholera vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Cholera vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Bacterial diseases</subject><subj-group><subject>Cholera</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Tropical diseases</subject><subj-group><subject>Neglected tropical diseases</subject><subj-group><subject>Cholera</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Africa</subject><subj-group><subject>South Sudan</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Commerce</subject><subj-group><subject>Procurement</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Asia</subject><subj-group><subject>India</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Africa</subject><subj-group><subject>Guinea</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review</article-title>
<alt-title alt-title-type="running-head">OCV Delivery Costs in Developing Countries</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0596-8072</contrib-id>
<name name-style="western">
<surname>Mogasale</surname>
<given-names>Vittal</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ramani</surname>
<given-names>Enusa</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wee</surname>
<given-names>Hyeseung</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Jerome H.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>International Vaccine Institute, Policy and Economic Research Department, SNU Research Park, Seoul, South Korea</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Korea Development Institute, Sejong-si, South Korea</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Ryan</surname>
<given-names>Edward T.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Massachusetts General Hospital, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> VM.</p></list-item>
<list-item><p><bold>Data curation:</bold> ER VM.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> ER HW VM.</p></list-item>
<list-item><p><bold>Funding acquisition:</bold> VM.</p></list-item>
<list-item><p><bold>Investigation:</bold> ER HW VM.</p></list-item>
<list-item><p><bold>Methodology:</bold> VM ER HW.</p></list-item>
<list-item><p><bold>Project administration:</bold> VM JK.</p></list-item>
<list-item><p><bold>Resources:</bold> VM JK.</p></list-item>
<list-item><p><bold>Software:</bold> ER.</p></list-item>
<list-item><p><bold>Supervision:</bold> VM JK.</p></list-item>
<list-item><p><bold>Validation:</bold> ER VM HW JK.</p></list-item>
<list-item><p><bold>Visualization:</bold> ER VM.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> ER VM.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> VM ER HW JK.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">vmogasale@ivi.int</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>8</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2016</year>
</pub-date>
<volume>10</volume>
<issue>12</issue>
<elocation-id>e0005124</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Mogasale et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0005124"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Use of the oral cholera vaccine (OCV) is a vital short-term strategy to control cholera in endemic areas with poor water and sanitation infrastructure. Identifying, estimating, and categorizing the delivery costs of OCV campaigns are useful in analyzing cost-effectiveness, understanding vaccine affordability, and in planning and decision making by program managers and policy makers.</p>
</sec>
<sec id="sec002">
<title>Objectives</title>
<p>To review and re-estimate oral cholera vaccination program costs and propose a new standardized categorization that can help in collation, analysis, and comparison of delivery costs across countries.</p>
</sec>
<sec id="sec003">
<title>Data sources</title>
<p>Peer reviewed publications listed in PubMed database, Google Scholar and World Health Organization (WHO) websites and unpublished data from organizations involved in oral cholera vaccination.</p>
</sec>
<sec id="sec004">
<title>Study eligibility criteria</title>
<p>The publications and reports containing oral cholera vaccination delivery costs, conducted in low- and middle-income countries based on World Bank Classification. Limits are humans and publication date before December 31<sup>st</sup>, 2014.</p>
</sec>
<sec id="sec005">
<title>Participants</title>
<p>No participants are involved, only costs are collected.</p>
</sec>
<sec id="sec006">
<title>Intervention</title>
<p>Oral cholera vaccination and cost estimation.</p>
</sec>
<sec id="sec007">
<title>Study appraisal and synthesis method</title>
<p>A systematic review was conducted using pre-defined inclusion and exclusion criteria. Cost items were categorized into four main cost groups: vaccination program preparation, vaccine administration, adverse events following immunization and vaccine procurement; the first three groups constituting the vaccine delivery costs. The costs were re-estimated in 2014 US dollars (US$) and in international dollar (I$).</p>
</sec>
<sec id="sec008">
<title>Results</title>
<p>Ten studies were identified and included in the analysis. The vaccine delivery costs ranged from US$0.36 to US$ 6.32 (in US$2014) which was equivalent to I$ 0.99 to I$ 16.81 (in I$2014). The vaccine procurement costs ranged from US$ 0.29 to US$ 29.70 (in US$2014), which was equivalent to I$ 0.72 to I$ 78.96 (in I$2014). The delivery costs in routine immunization systems were lowest from US$ 0.36 (in US$2014) equivalent to I$ 0.99 (in I$2014).</p>
</sec>
<sec id="sec009">
<title>Limitations</title>
<p>The reported cost categories are not standardized at collection point and may lead to misclassification. Costs for some OCV campaigns are not available and analysis does not include direct and indirect costs to vaccine recipients.</p>
</sec>
<sec id="sec010">
<title>Conclusions and implications of key findings</title>
<p>Vaccine delivery cost estimation is needed for budgeting and economic analysis of vaccination programs. The cost categorization methodology presented in this study is helpful in collecting OCV delivery costs in a standardized manner, comparing delivery costs, planning vaccination campaigns and informing decision-making.</p>
</sec>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>We reviewed and re-estimated oral cholera vaccine delivery costs in low and middle income countries standardizing cost categories. The cost categorization proposed here can help in collation, analysis, comparison and economic analysis of OCV delivery costs across countries.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008309</institution-id>
<institution>Johns Hopkins Bloomberg School of Public Health</institution>
</institution-wrap>
</funding-source>
<award-id>CHJOH05064-010</award-id>
</award-group>
<funding-statement>This work was conducted as part of the Delivering Oral Vaccine Effectively (DOVE) Initiative (<ext-link ext-link-type="uri" xlink:href="https://www.stopcholera.org/" xlink:type="simple">https://www.stopcholera.org/</ext-link>), funded by the Bill and Melinda Gates Foundation through the Johns Hopkins University Bloomberg School of Public Health (Grant CHJOH05064-010). The International Vaccine Institute received funding support from the Government of the Republic of Korea and the Government of Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec011" sec-type="intro">
<title>Introduction</title>
<p>Cholera is transmitted through the fecal-oral route, and humans are the natural host. It is caused by the ingestion of O1 and less commonly O139 serogroups of the <italic>Vibrio cholerae</italic> bacterium and characterized by severe, potentially life-threatening diarrhea [<xref ref-type="bibr" rid="pntd.0005124.ref001">1</xref>]. The disease inflicts a significant health burden on many low-and-middle-income countries (LMICs) in settings where food and water are contaminated with human feces. Infrastructure disruption resulting from natural disasters, civil unrest, and war often precipitates cholera outbreaks, particularly in settings where there is endemic cholera risk. Cholera outbreak risk is further increased when infrastructure disruption is superimposed on the poor sanitation and unsafe drinking water found in parts of Africa, Asia, and South and Central America [<xref ref-type="bibr" rid="pntd.0005124.ref002">2</xref>]. While improving water and sanitation infrastructure would greatly enhance the control of cholera in the long-term, the use of preventive vaccines has shown promise in the interim [<xref ref-type="bibr" rid="pntd.0005124.ref003">3</xref>–<xref ref-type="bibr" rid="pntd.0005124.ref005">5</xref>].</p>
<p>The struggle to develop a safe and effective cholera vaccine that can prevent and control the disease has a long history. Injectable whole-cell cholera vaccines were developed as early as the 19<sup>th</sup> century and extensively used in the 20<sup>th</sup> century in the Indian subcontinent and later abandoned due to their limited efficacy and systemic adverse events [<xref ref-type="bibr" rid="pntd.0005124.ref006">6</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref007">7</xref>]. Subsequently, a new generation of live-attenuated or killed oral cholera vaccines were developed, licensed, and deployed. A killed whole-cell cholera vaccine with recombinant B subunit of cholera toxin (Dukoral) was licensed in 1991 (two-dose regimen for &gt;2 years of age) [<xref ref-type="bibr" rid="pntd.0005124.ref006">6</xref>] and used by travelers visiting cholera-endemic regions. This vaccine received World Health Organization (WHO) prequalification in 2001 and has a price of $5 per dose on the public market. Meanwhile, Vietnam developed and deployed a locally manufactured OCV, ORC-Vax [<xref ref-type="bibr" rid="pntd.0005124.ref008">8</xref>]. The vaccine was licensed in 1997 in Vietnam and was modified to mORC-Vax in 2009 after improving the production process. Currently, the price of this vaccine is US$1.25 per dose on Vietnam’s public market. At the same time, international efforts were made to reformulate ORC-Vax into a less expensive modified killed whole-cell OCV, which was first licensed in India in 2009 (Shanchol, two-dose regimen for &gt;1 year of age), and later WHO-prequalified in 2011. Currently, the price of this vaccine is $1.85 per dose on the public market worldwide. A WHO OCV stockpile was then created in 2013 to make the vaccine available and affordable in emergency settings [<xref ref-type="bibr" rid="pntd.0005124.ref009">9</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref010">10</xref>]. These two WHO-prequalified OCVs, Dukoral and Shanchol have been deployed in mass vaccination campaigns across many endemic regions either pre-emptively or reactively; notably in Haiti, Comoros, Indonesia, Uganda, Mozambique, Tanzania, India, Bangladesh, Guinea, South Sudan, Malawi, Thailand, Ethiopia and Nepal [<xref ref-type="bibr" rid="pntd.0005124.ref011">11</xref>–<xref ref-type="bibr" rid="pntd.0005124.ref021">21</xref>].</p>
<p>A cholera vaccination can be broken down into several small and large activities or actions. Understanding the activities involved in vaccination campaigns and estimating cost of each key activity is vital in planning and deployment of OCVs. When deploying a new vaccine, besides routine recurrent costs, the introduction cost such as initial planning, extra logistics and cold chain, training, social mobilization, sensitization, and other new implementation activities such as management of Adverse Events Following Immunization (AEFI) should be considered [<xref ref-type="bibr" rid="pntd.0005124.ref022">22</xref>]. Analysis of cost items helps to identify major cost drivers in mass vaccination programs which are critical elements in planning program implementation. This research intends to assess the costs of the different activities required for OCV delivery in LMICs based on systematic literature search and collection of unpublished data from organizations involved in oral cholera vaccination. We propose to categorize cost items in a standardized method and re-estimate delivery costs. Through this analysis we recommend a standardized cost-collation approach for OCV campaigns that can be used in developing OCV delivery cost-estimation tools and comparing costs across different geographical regions.</p>
</sec>
<sec id="sec012" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec013">
<title>Search strategy and selection criteria</title>
<p>A systematic literature review was conducted using search terms (vaccination cost) AND (cholera) in Medline database through PubMed restricting search to humans and dated up to December 31, 2014. Detailed search terms are (("vaccination"[MeSH Terms] OR "vaccination"[All Fields]) AND ("economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields])) AND ("cholera"[MeSH Terms] OR "cholera"[All Fields]) AND (("0001/01/01"[PDAT]: "2014/12/31"[PDAT]) AND "humans"[MeSH Terms]). After initial screening on title and abstract, studies using Dukoral, ORC-Vax and Shanchol conducted in LMICs as per the World Bank’s classification [<xref ref-type="bibr" rid="pntd.0005124.ref023">23</xref>] that quantified the costing items in cholera vaccination were included. We excluded costing or cost-effectiveness analyses that used simulated or assumed costs, studies that referred to traveler’s vaccination, and studies that considered vaccination in developed countries. The systematic review followed PRISMA guidelines [<xref ref-type="bibr" rid="pntd.0005124.ref024">24</xref>] (<xref ref-type="supplementary-material" rid="pntd.0005124.s001">S1 Checklist</xref>). In addition, to find unpublished literature, we searched the Google Scholar and WHO website for OCV mass campaign-related publications and contacted organizations involved in OCV campaigns, including the International Vaccine Institute (IVI), Medecine sans Frontieres (MSF), and the US Centers for Disease Control and Prevention to obtain available reports.</p>
</sec>
<sec id="sec014">
<title>Categorization of immunization costs</title>
<p>We categorized cost items into four groups with subcategories in each based on the chronological order of implementing OCV campaigns using standardized definitions (<xref ref-type="table" rid="pntd.0005124.t001">Table 1</xref>). Vaccination program preparation costs were incurred in field capacity building which includes microplanning, training of personnel, community sensitization, social mobilization and other costs like the storage of vaccines in central warehouses prior to vaccination implementation. Vaccine administration costs included actual vaccine administration costs in the field to individuals as well as transportation of the vaccines from central warehouse to field headquarters and to vaccination field sites. The cost items included are conveyance, per-diem, logistic arrangement, equipment, and location costs for vaccine administration, supervision and monitoring. Finally, all costs related to the AEFI management were included under this category. The last three categories constitute vaccine delivery costs. The vaccine procurement costs included cost of vaccine purchase at preclearance and add-on which comprised costs of freight, insurance, taxes, and customs. This categorization allows comparison of cholera vaccination campaign expenditures across countries that have deployed the vaccines. The financial costs of OCV campaigns were used in our analysis as no opportunity costs were taken into consideration.</p>
<table-wrap id="pntd.0005124.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0005124.t001</object-id>
<label>Table 1</label> <caption><title>Cost categorization of oral cholera vaccination campaigns.</title></caption>
<alternatives>
<graphic id="pntd.0005124.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0005124.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Main cost category</th>
<th align="left">Sub cost categories</th>
<th align="left">Details of cost items<xref ref-type="table-fn" rid="t001fn001">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="5">1. Vaccination program preparation costs</td>
<td align="left">Micro-planning</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Remuneration, travel allowances and per diem for planners,</p></list-item>
<list-item><p>Venue rental (cost) for planning meetings,</p></list-item>
<list-item><p>Computers and office furniture for planning</p></list-item>
<list-item><p>Census update</p></list-item>
<list-item><p>Transportation costs</p></list-item>
<list-item><p>Administration costs</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Training</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Remuneration, travel allowances and per diems for trainers and participants</p></list-item>
<list-item><p>Manuals and guides for training</p></list-item>
<list-item><p>Venue rental for training, Transportation costs</p></list-item>
<list-item><p>Administration costs</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Sensitization</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Representations/ participation meetings at various levels</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Social mobilization</td>
<td align="left">
<list list-type="bullet">
<list-item><p>House-to-house visits</p></list-item>
<list-item><p>Communication through print materials,</p></list-item>
<list-item><p>Radio, television, mobile and internet</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Other preparations</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Vaccine handling charges at central store</p></list-item>
<list-item><p>Cold chain equipment purchase or renting</p></list-item>
<list-item><p>Salaries of regional and local vaccination planning management staff</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left" rowspan="6">2. Vaccine administration costs</td>
<td align="left">Vaccine logistics and cold chain</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Vaccine transport from country headquarters (central warehouse) to field headquarters and to vaccination field sites</p></list-item>
<list-item><p>Staff allowance related vaccine storage</p></list-item>
<list-item><p>Staff allowances related vaccine transport</p></list-item>
<list-item><p>Vaccine storage cost at field headquarters or site</p></list-item>
<list-item><p>Cold chain related costs at field headquarters and site</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Materials and supplies</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Water and cups for water</p></list-item>
<list-item><p>Soap for hand wash</p></list-item>
<list-item><p>Incentives to improve active participation</p></list-item>
<list-item><p>Vaccination cards, markers, supplies for data entry, consent form</p></list-item>
<list-item><p>Logistic materials for the site</p></list-item>
<list-item><p>Any other material provided with the purpose of aiding vaccine administration</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Site preparation</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Venue rental (cost) for vaccination</p></list-item>
<list-item><p>Cleaning and vaccination booth setup</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Vaccine administration</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Salary of staff involved in the vaccine administration,Per diem and other allowances including food and refreshment</p></list-item>
<list-item><p>Labour cost for hired local staff per diem and allowances</p></list-item>
<list-item><p>Transportation costs</p></list-item>
<list-item><p>Administration costs</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Supervision and monitoring</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Salary of staff involved in the vaccine administration</p></list-item>
<list-item><p>Per diem and allowances including food and refreshments</p></list-item>
<list-item><p>Labour cost for hired local staff per diem and allowances</p></list-item>
<list-item><p>Review meetings</p></list-item>
<list-item><p>Transportation costs</p></list-item>
<list-item><p>Administration costs</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Waste management</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Waste management</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left" rowspan="2">3. AEFI management</td>
<td align="left">AEFI monitoring by trained staff</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Salary for staff involved in the AEFI management</p></list-item>
<list-item><p>Per diem and allowances including food and refreshments</p></list-item>
<list-item><p>Transportation costs for monitoring</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Medical and advisory service provision</td>
<td align="left">
<list list-type="bullet">
<list-item><p>AEFI management related transport costs</p></list-item>
<list-item><p>Health service delivery costs</p></list-item>
<list-item><p>Medicine and laboratory investigations</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left" rowspan="2">4. Vaccine procurement</td>
<td align="left">Vaccine price</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Vaccine price at pre-clearance</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
<tr>
<td align="left">Shipment related costs</td>
<td align="left">
<list list-type="bullet">
<list-item><p>Costs of freight</p></list-item>
<list-item><p>Insurance</p></list-item>
<list-item><p>Taxes</p></list-item>
<list-item><p>Clearance charges</p></list-item>
<list-item><p>Pre-clearance storage cost</p></list-item>
<list-item><p>Transport to central storage</p></list-item>
<list-item><p>Others (write description)</p></list-item>
</list></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>* Costs related to staff from international organizations and research organizations are to be excluded.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec015">
<title>Re-estimation of costs</title>
<p>After categorizing costs from each paper we summarized the results and presented overall vaccination program costs as the sum of all four cost categories. As vaccines are often donated to countries, we differentiated overall vaccination program costs and vaccine delivery costs by segregating vaccine procurement costs. We estimated program cost and vaccine delivery cost per person for complete vaccination using three methods: 1) in United States Dollars (US$) as reported in the literature for the campaign year, 2) in 2014 US$ after adjusting for country level inflation and current exchange rate, and 3) in 2014 international dollars (I$) after adjusting for country level inflation and current purchasing power parity. The year 2014 was selected as the base year for cost analysis.</p>
<p>In Method 1, we presented costs as recorded by the investigators for the campaign year (campaign year cost) in US$. Costs in local currency units (LCU) were converted to US$ based on the World Bank exchange rate reference database for that year [<xref ref-type="bibr" rid="pntd.0005124.ref025">25</xref>]. In Method 2, we adjusted the base year costs to 2014 US$ cost-equivalent by first converting the costs to LCU for the vaccination year using the US$-LCU exchange rate for that year and inflating it to year 2014 based on the country inflation rate (inflation, consumer prices, annual %) using the World Bank inflation data [<xref ref-type="bibr" rid="pntd.0005124.ref025">25</xref>]. The adjusted results were presented in US$ 2014 after converting LCU to US$ based on the 2014 exchange rate. In Method 3, we adjusted the campaign year cost to the 2014 I$ cost-equivalent by first converting the costs to LCU for the vaccination year, and then inflating to the year 2014 as described for Method 2. The adjusted results were presented in I$ after converting LCU to I$ for 2014 [<xref ref-type="bibr" rid="pntd.0005124.ref026">26</xref>].</p>
<p>We employed three methods of program cost estimation for two reasons. First, costs from different campaign years and different countries are not comparable and therefore need to be adjusted to the same base year in order to eliminate inflation effects [<xref ref-type="bibr" rid="pntd.0005124.ref027">27</xref>]. Second, the exchange rate conversion does not always consider the differences in the cost of living between countries [<xref ref-type="bibr" rid="pntd.0005124.ref028">28</xref>]. For example, the vaccination personnel costs (e.g., per diem) vary by country, which cannot be adequately captured in US$. Purchasing power parity expressed in I$, defined as the number of units of a country’s currency required to buy the same amounts of goods and services in the domestic market as US$ would buy in the United States [<xref ref-type="bibr" rid="pntd.0005124.ref028">28</xref>], allows comparison across countries.</p>
</sec>
</sec>
<sec id="sec016" sec-type="results">
<title>Results</title>
<sec id="sec017">
<title>Systematic review</title>
<p>We identified 83 papers on PubMed search, of which eight were included based on the inclusion-exclusion criteria and two papers were obtained from other sources and personal communications (<xref ref-type="supplementary-material" rid="pntd.0005124.s002">S1 Flowchart</xref>). The program costs for Shanchol delivery were available from four countries (five campaigns) that deployed the vaccine in 2011 and 2014 (<xref ref-type="table" rid="pntd.0005124.t002">Table 2</xref>) [<xref ref-type="bibr" rid="pntd.0005124.ref015">15</xref>–<xref ref-type="bibr" rid="pntd.0005124.ref017">17</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref021">21</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref029">29</xref>]. A publication presented OCV delivery cost summary for a campaign conducted in three internally displaced people (IDP) camps in 2014 in South Sudan without detailed cost categorization [<xref ref-type="bibr" rid="pntd.0005124.ref021">21</xref>]. We also obtained more detailed delivery cost for another OCV campaign conducted in South Sudan in 2013 from personal communications [<xref ref-type="bibr" rid="pntd.0005124.ref029">29</xref>]. We were aware that in Ethiopia and Malawi, OCV campaigns were conducted in 2015 and delivery costs were estimated [<xref ref-type="bibr" rid="pntd.0005124.ref018">18</xref>], but data was unavailable. The program costs for Dukoral were available from four countries that deployed vaccines from 1997 to 2009 [<xref ref-type="bibr" rid="pntd.0005124.ref012">12</xref>–<xref ref-type="bibr" rid="pntd.0005124.ref014">14</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref020">20</xref>]. The data for Indonesia was obtained from WHO website [<xref ref-type="bibr" rid="pntd.0005124.ref020">20</xref>]. In reference review we found one paper presenting a brief description of a Dukoral campaign in Darfur in 2014 stating direct cost of vaccination was US$336,527 or US$ 7 per full vaccinated person [<xref ref-type="bibr" rid="pntd.0005124.ref030">30</xref>]. We had to exclude this study from further analysis because costs could not be categorized. The program costs for ORC-Vax were available from Vietnam that deployed vaccine in a 1998 campaign [<xref ref-type="bibr" rid="pntd.0005124.ref031">31</xref>].</p>
<table-wrap id="pntd.0005124.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0005124.t002</object-id>
<label>Table 2</label> <caption><title>Oral cholera vaccination costs as reported, adjusted to US$ 2014 and adjusted to 2014 international dollars.</title></caption>
<alternatives>
<graphic id="pntd.0005124.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0005124.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left"><bold><italic>Shanchol</italic></bold></td>
<td align="left" colspan="3"><bold><italic>India</italic>, <italic>2011</italic></bold> [<xref ref-type="bibr" rid="pntd.0005124.ref015">15</xref>]</td>
<td align="left" colspan="3"><bold><italic>Bangladesh</italic>, <italic>2011</italic></bold>[<xref ref-type="bibr" rid="pntd.0005124.ref016">16</xref>]<xref ref-type="table-fn" rid="t002fn009"><sup>c</sup></xref></td>
<td align="left" colspan="3"><bold><italic>Guinea</italic>, <italic>2012</italic></bold>[<xref ref-type="bibr" rid="pntd.0005124.ref017">17</xref>] <xref ref-type="table-fn" rid="t002fn009"><sup>c</sup></xref></td>
<td align="left" colspan="3"><bold><italic>South Sudan</italic>, <italic>2013</italic></bold>[<xref ref-type="bibr" rid="pntd.0005124.ref029">29</xref>]<xref ref-type="table-fn" rid="t002fn009"><sup>c</sup></xref></td>
<td align="left" colspan="3"><bold><italic>South Sudan, 2014 [<xref ref-type="bibr" rid="pntd.0005124.ref021">21</xref>]</italic></bold> <xref ref-type="table-fn" rid="t002fn009"><sup>c</sup></xref></td>
</tr>
<tr>
<td align="left">Number fully immunized</td>
<td align="left" colspan="3">23,751</td>
<td align="left" colspan="3">123,661</td>
<td align="left" colspan="3">143,706</td>
<td align="left" colspan="3">71,912</td>
<td align="left" colspan="3">60,421</td>
</tr>
<tr>
<td align="left">Vaccination setting</td>
<td align="left" colspan="3">Preemptive, rural</td>
<td align="left" colspan="3">Preemptive, urban</td>
<td align="left" colspan="3">Reactive, rural</td>
<td align="left" colspan="3">Preemptive, refugee camp, rural</td>
<td align="left" colspan="3">Preemptive, internally displaced people</td>
</tr>
<tr>
<td align="left">Costing perspective</td>
<td align="left" colspan="3">Government</td>
<td align="left" colspan="3">Implementing agency</td>
<td align="left" colspan="3">Implementing agency</td>
<td align="left" colspan="3">Implementing agency</td>
<td align="left" colspan="3">Implementing agency</td>
</tr>
<tr>
<td align="left"/>
<td align="left"><italic>Method 1</italic></td>
<td align="left"><italic>Method</italic> 2</td>
<td align="left"><italic>Method</italic> 3</td>
<td align="left"><italic>Method</italic> 1</td>
<td align="left"><italic>Method</italic> 2</td>
<td align="left"><italic>Method</italic> 3</td>
<td align="left"><italic>Method</italic> 1</td>
<td align="left"><italic>Method</italic> 2</td>
<td align="left"><italic>Method</italic> 3</td>
<td align="left"><italic>Method</italic> 1<xref ref-type="table-fn" rid="t002fn012"><sup>f</sup></xref></td>
<td align="left"><italic>Method</italic> 2</td>
<td align="left"><italic>Method</italic> 3</td>
<td align="left"><italic>Method</italic> 1<xref ref-type="table-fn" rid="t002fn013"><sup>g</sup></xref></td>
<td align="left"><italic>Method</italic> 2</td>
<td align="left"><italic>Method</italic> 3</td>
</tr>
<tr>
<td align="left"><xref ref-type="table-fn" rid="t002fn004">**</xref><bold>Currency unit</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
</tr>
<tr>
<td align="left">Price per dose</td>
<td align="left">1.00</td>
<td align="left">1.01</td>
<td align="left">3.60</td>
<td align="left">1.00</td>
<td align="left">1.21</td>
<td align="left">3.45</td>
<td align="left">1.00</td>
<td align="left">1.22</td>
<td align="left">2.75</td>
<td align="left">2.40</td>
<td align="left">1.94</td>
<td align="left">9.16</td>
<td align="left">1.85</td>
<td align="left">1.85</td>
<td align="left">7.06</td>
</tr>
<tr>
<td align="left">1.Vaccination Program Preparation Cost</td>
<td align="left">5,603</td>
<td align="left">5,655</td>
<td align="left">20,163</td>
<td align="left">17,775</td>
<td align="left">21,465</td>
<td align="left">61,314</td>
<td align="left">4,899</td>
<td align="left">5,995</td>
<td align="left">13,474</td>
<td align="left">103,248</td>
<td align="left">83,568</td>
<td align="left">393,856</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">1.1 Microplanning</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">11,915</td>
<td align="left">14,388</td>
<td align="left">41,100</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">47,250</td>
<td align="left">38,244</td>
<td align="left">180,243</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">1.2 Training</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">3,013</td>
<td align="left">3,638</td>
<td align="left">10,393</td>
<td align="left">4,899</td>
<td align="left">5,995</td>
<td align="left">13,474</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">1.3 Sensitization &amp; Social Mobilization</td>
<td align="left">5,603</td>
<td align="left">5,655</td>
<td align="left">20,163</td>
<td align="left">2,847</td>
<td align="left">3,438</td>
<td align="left">9,822</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">4,488</td>
<td align="left">3,633</td>
<td align="left">17,120</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">1.4 Other Preparation Costs</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">51,510</td>
<td align="left">41,692</td>
<td align="left">196,492</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">2.Vaccine Administration Cost</td>
<td align="left">17,103</td>
<td align="left">17,261</td>
<td align="left">61,548</td>
<td align="left">183,858<xref ref-type="table-fn" rid="t002fn008"><sup>b</sup></xref></td>
<td align="left">222,029</td>
<td align="left">634,226</td>
<td align="left">268,087<xref ref-type="table-fn" rid="t002fn007"><sup>a</sup></xref></td>
<td align="left">328,079</td>
<td align="left">737,346</td>
<td align="left">168,113</td>
<td align="left">136,069</td>
<td align="left">641,293</td>
<td align="left">104,000</td>
<td align="left">104,000</td>
<td align="left">396,723</td>
</tr>
<tr>
<td align="left">3.AEFI Cost</td>
<td align="left">4,237</td>
<td align="left">4,276</td>
<td align="left">15,247</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left"><xref ref-type="table-fn" rid="t002fn005">***</xref>Total OCV Delivery (Unit) Cost</td>
<td align="left">26,943 (1.13)</td>
<td align="left">27,192 (1.14)</td>
<td align="left">96,958 (4.08)</td>
<td align="left">201,633 (1.63)</td>
<td align="left">243,494 (1.97)</td>
<td align="left">695,540 (5.62)</td>
<td align="left">272,986 (1.90)</td>
<td align="left">334,074 (2.32)</td>
<td align="left">750,820 (5.22)</td>
<td align="left">271,362<xref ref-type="table-fn" rid="t002fn001">¶</xref> (3.77)</td>
<td align="left">219,638 (3.05)</td>
<td align="left">1,035,148 (14.39)</td>
<td align="left">104,000 (1.72)</td>
<td align="left">104,000 (1.72)</td>
<td align="left">396,723 (6.57)</td>
</tr>
<tr>
<td align="left">4.Vaccine Procurement Cost</td>
<td align="left">122,629</td>
<td align="left">123,762</td>
<td align="left">441,298</td>
<td align="left">284,529</td>
<td align="left">343,600</td>
<td align="left">981,493</td>
<td align="left">642,356</td>
<td align="left">786,102</td>
<td align="left">1,766,734</td>
<td align="left">666,980</td>
<td align="left">539,848</td>
<td align="left">2,544,291</td>
<td align="left">491,048</td>
<td align="left">481,048</td>
<td align="left">1,873,172</td>
</tr>
<tr>
<td align="left">Total OCV Program (Unit) Cost</td>
<td align="left">149,572 (6.30)</td>
<td align="left">150,954 (6.36)</td>
<td align="left">538,256 (22.66)</td>
<td align="left">486,162 (3.93)</td>
<td align="left">587,094 (4.75)</td>
<td align="left">1,677,034 (13.56)</td>
<td align="left">915,342 (6.37)</td>
<td align="left">1,120,176 (7.79)</td>
<td align="left">2,517,554 (17.52)</td>
<td align="left">938,342 (13.05)</td>
<td align="left">759,485 (10.56)</td>
<td align="left">3,579,440 (49.78)</td>
<td align="left">595,048 (5.62)</td>
<td align="left">595,048 (5.62)</td>
<td align="left">2,269,896 (21.43)</td>
</tr>
<tr>
<td align="left"><bold><italic>Dukoral/ ORC-Vax/mORC-Vax</italic></bold></td>
<td align="left" colspan="3"><bold><italic>Dukoral</italic>, <italic>Uganda</italic>, <italic>1997</italic></bold>[<xref ref-type="bibr" rid="pntd.0005124.ref012">12</xref>] <xref ref-type="table-fn" rid="t002fn010"><sup>d</sup></xref></td>
<td align="left" colspan="3"><bold><italic>Dukoral</italic>, <italic>Mozambique</italic>, <italic>2003</italic></bold>[<xref ref-type="bibr" rid="pntd.0005124.ref013">13</xref>]</td>
<td align="left" colspan="3"><bold><italic>Dukoral</italic>, <italic>Indonesia</italic>, <italic>2005</italic></bold> [<xref ref-type="bibr" rid="pntd.0005124.ref020">20</xref>]</td>
<td align="left" colspan="3"><bold><italic>Dukoral</italic>, <italic>Tanzania</italic>, <italic>2009</italic></bold> [<xref ref-type="bibr" rid="pntd.0005124.ref014">14</xref>]</td>
<td align="left" colspan="3"><bold><italic>ORC-Vax/mORC-Vax, Vietnam, 1997–2012 [<xref ref-type="bibr" rid="pntd.0005124.ref031">31</xref>]</italic></bold></td>
</tr>
<tr>
<td align="left">Number fully immunized</td>
<td align="left" colspan="3"><italic>27</italic>,<italic>607</italic></td>
<td align="left" colspan="3"><italic>44</italic>,<italic>156</italic></td>
<td align="left" colspan="3"><italic>54</italic>,<italic>627</italic></td>
<td align="left" colspan="3"><italic>23</italic>,<italic>921</italic></td>
<td align="left" colspan="3"><italic>118</italic>,<italic>555</italic></td>
</tr>
<tr>
<td align="left">Vaccination setting</td>
<td align="left" colspan="3">Preemptive, refugee camp, rural</td>
<td align="left" colspan="3">Preemptive, urban</td>
<td align="left" colspan="3">Preemptive, internally displaced people</td>
<td align="left" colspan="3">Preemptive, urban &amp; rural</td>
<td align="left" colspan="3">Preemptive &amp; reactive, urban &amp; rural</td>
</tr>
<tr>
<td align="left">Costing perspective</td>
<td align="left" colspan="3">Implementing agency</td>
<td align="left" colspan="3">Implementing agency</td>
<td align="left" colspan="3">Implementing agency/government</td>
<td align="left" colspan="3">Government</td>
<td align="left" colspan="3">Government</td>
</tr>
<tr>
<td align="left"><bold>Currency unit</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold><xref ref-type="table-fn" rid="t002fn004">**</xref></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>US$</bold></td>
<td align="left"><bold>Int. $</bold> <xref ref-type="table-fn" rid="t002fn004">**</xref></td>
</tr>
<tr>
<td align="left">Price per dose</td>
<td align="left"><italic>Free</italic></td>
<td align="left"><italic>Free</italic></td>
<td align="left"><italic>Free</italic></td>
<td align="left"><italic>Free</italic></td>
<td align="left"><italic>Free</italic></td>
<td align="left"><italic>Free</italic></td>
<td align="left">4.70</td>
<td align="left">7.23</td>
<td align="left">21.77</td>
<td align="left"><italic>5</italic>.<italic>00</italic></td>
<td align="left">6.70</td>
<td align="left">17.82</td>
<td align="left">0.31</td>
<td align="left">0.61</td>
<td align="left">1.68</td>
</tr>
<tr>
<td align="left">1.Vaccination Program Preparation Cost</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">11,545</td>
<td align="left">18,650</td>
<td align="left">35,226</td>
<td align="left">8,812</td>
<td align="left">13,550</td>
<td align="left">40,811</td>
<td align="left">21,820</td>
<td align="left">29,251</td>
<td align="left">77,766</td>
<td align="left">4,027</td>
<td align="left">7,953</td>
<td align="left">21,812</td>
</tr>
<tr>
<td align="left">1.1 Microplanning</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">4,423</td>
<td align="left">6,801</td>
<td align="left">20,484</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">1.2 Training</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">9,470</td>
<td align="left">12,695</td>
<td align="left">33,751</td>
<td align="left">3,304</td>
<td align="left">6,525</td>
<td align="left">17,896</td>
</tr>
<tr>
<td align="left">1.3 Sensitization &amp; Social Mobilization</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">9,710</td>
<td align="left">15,686</td>
<td align="left">29,627</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">12,350</td>
<td align="left">16,556</td>
<td align="left">44,015</td>
<td align="left">723</td>
<td align="left">1,428</td>
<td align="left">3,916</td>
</tr>
<tr>
<td align="left">1.4 Other Preparation Costs</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">1,835</td>
<td align="left">2,964</td>
<td align="left">5,599</td>
<td align="left">4,389</td>
<td align="left">6,749</td>
<td align="left">20,327</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">2.Vaccine Administration Cost</td>
<td align="left">8,634</td>
<td align="left">11,317</td>
<td align="left">28,692</td>
<td align="left">47,998</td>
<td align="left">77,539</td>
<td align="left">146,450</td>
<td align="left">160,360</td>
<td align="left">246,589</td>
<td align="left">742,681</td>
<td align="left">91,000</td>
<td align="left">121,992</td>
<td align="left">324,320</td>
<td align="left">17,720</td>
<td align="left">34,994</td>
<td align="left">95,980</td>
</tr>
<tr>
<td align="left">3.AEFI Cost</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left"><xref ref-type="table-fn" rid="t002fn005">***</xref>Total OCV Delivery (Unit) Cost</td>
<td align="left">8,634 (0.31)</td>
<td align="left">11,317 (0.41)</td>
<td align="left">28,692 (1.04)</td>
<td align="left">59,543 (1.35)</td>
<td align="left">96,189 (2.18)</td>
<td align="left">181,676 (4.11)</td>
<td align="left">169,172<xref ref-type="table-fn" rid="t002fn001">¶</xref> (3.10)</td>
<td align="left">260,140 (4.76)</td>
<td align="left">783,492 (14.34)</td>
<td align="left">112,820<xref ref-type="table-fn" rid="t002fn001">¶</xref> (4.72)</td>
<td align="left">151,243 (6.32)</td>
<td align="left">402,086 (16.81)</td>
<td align="left">21,747 (0.18)</td>
<td align="left">42,947 (0.36)</td>
<td align="left">117,792 (0.99)</td>
</tr>
<tr>
<td align="left">4.Vaccine Procurement Cost</td>
<td align="left">6,021</td>
<td align="left">7,892</td>
<td align="left">20,009</td>
<td align="left">35,136</td>
<td align="left">56,761</td>
<td align="left">107,206</td>
<td align="left">665,247<xref ref-type="table-fn" rid="t002fn011"><sup>e</sup></xref></td>
<td align="left">1,022,967</td>
<td align="left">3,080,981</td>
<td align="left">530,000</td>
<td align="left">710,501</td>
<td align="left">1,888,897</td>
<td align="left">83,700</td>
<td align="left">165,293</td>
<td align="left">453,360</td>
</tr>
<tr>
<td align="left">Total OCV Program (Unit) Cost</td>
<td align="left">14,655 (0.53)</td>
<td align="left">19,208 (0.70)</td>
<td align="left">48,701 (1.76)</td>
<td align="left">94,679 (2.14)</td>
<td align="left">152,950 (3.46)</td>
<td align="left">288,882 (6.54)</td>
<td align="left">834,419 (15.27)</td>
<td align="left">1,283,106 (23.49)</td>
<td align="left">3,864,473 (70.74)</td>
<td align="left">642,820 (26.87)</td>
<td align="left">861,744 (36.02)</td>
<td align="left">2,290,983 (95.77)</td>
<td align="left">105,447 (0.89)</td>
<td align="left">208,240 (1.76)</td>
<td align="left">571,153 (4.82)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><sup>¶</sup> International consultant cost excluded</p></fn>
<fn id="t002fn002"><p>Note: NA = information not available.</p></fn>
<fn id="t002fn003"><p>Method 1 reports the survey year costs (US$) presented in the published papers; Method 2 reports the amount after adjusting for country level inflation and converting to 2014 exchange rate (US$); Method 3 after adjusting for inflation and converting to 2014 PPP rate (international dollars).</p></fn>
<fn id="t002fn004"><p>**Int. $ = International $</p></fn>
<fn id="t002fn005"><p>***Excludes vaccine purchase cost and other vaccine procurement costs.</p></fn>
<fn id="t002fn006"><p>South Sudan (EUR 133,916.74 <italic>≈</italic> US$ 182,570), Indonesia (US$ 124,230) and Tanzania (US$ 110,000) had international consultant costs. In Bangladesh, vaccine storage was covered by the EPI free of charge.</p></fn>
<fn id="t002fn007"><p><sup>a</sup> Vaccine administration cost for Guinea also includes parts of the sensitization cost (payments to the sensitization team)</p></fn>
<fn id="t002fn008"><p><sup>b</sup> Bangladesh vaccine administration cost (staff salary) include cost for census update</p></fn>
<fn id="t002fn009"><p><sup>c</sup> Bangladesh (passive surveillance), Guinea and South Sudan monitored adverse event following immunization but did not report associated costs</p></fn>
<fn id="t002fn010"><p><sup>d</sup> Uganda vaccination did not account costs for cold chain (existing cold chain was used at Entebbe, the international arrival point and no cold chain was used at field site), and costs for social mobilization, microplanning and training (carried out by non-governmental organizations). Freight cost includes tax and insurance.</p></fn>
<fn id="t002fn011"><p><sup>e</sup> For Indonesia vaccine cost includes cups for drinking, excludes international experts’ cost (WHO), vaccine administration cost includes staff training and material cost, costing was done from donor’s (WHO) perspective</p></fn>
<fn id="t002fn012"><p><sup>f</sup> Costing for South Sudan was conducted using Euro currency rates. This was converted to US$ rates for February 2, 2013 from oanda.com/currency/converter/: 1Euro to US$ 1.36331</p></fn>
<fn id="t002fn013"><p><sup>g</sup> Costs were not detailed, presented only three cost categories; vaccine price, vaccine shipment and vaccine administration. Total 121,729 doses of Shanchol purchased was not used and the cost is not included in the table.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The number of fully vaccinated people per campaign ranged from 23,751 in India to 143,706 in Guinea. The reported price per dose of Shanchol procurement varied from US$ 1.00 to US$ 2.40 while the price of Dukoral ranged from US$ 0 (free) to US$ 5.00.</p>
</sec>
<sec id="sec018">
<title>Categorization of costs</title>
<p>The cost categorization and presentation was inconsistent across the studies conducted as shown in <xref ref-type="table" rid="pntd.0005124.t002">Table 2</xref>, limiting their comparability. AEFI management, micro-planning, training, sensitization and social mobilization were often mentioned as activities, but costs were merged with other categories which we could not de-merge. In India, micro-planning was considered as a management activity for existing staff and costs were excluded. In Bangladesh and South Sudan, expenses on office furniture and office supplies were categorized under micro-planning while Indonesia had purchased a computer, which was classified as costs for micro-planning. Costs related to AEFI management were reported only from India, representing 15.73% of the total OCV delivery costs.</p>
<p>Of the four major cost categories, vaccine procurement was the costliest component in all OCV campaigns. Whereas, the vaccine administration was the costliest item under vaccine delivery costs (<xref ref-type="table" rid="pntd.0005124.t002">Table 2</xref>). Staff salary and allowance when reported, material and supplies such as vaccination card followed by plastic cups, water and soap, when used, were the cost drivers for vaccine administration. Staff salary and allowances are among the costliest items ranging from 23.6% to 87.8% of delivery costs in Guinea and India, respectively. The material and supplies costed 43.9%, 42.1% and 37.0% of delivery costs in Tanzania, South Sudan (2013) and Uganda respectively.</p>
</sec>
<sec id="sec019">
<title>Re-estimation of costs</title>
<p>Costs re-estimated in US$2014 shows high variability of delivery costs across the sites (<xref ref-type="fig" rid="pntd.0005124.g001">Fig 1</xref>, <xref ref-type="table" rid="pntd.0005124.t002">Table 2</xref>). The variability of delivery costs within the same country was also prominent. Although average delivery cost of OCV campaign in South Sudan IDP camps was $1.72 in US$ 2014 (I$6.57) [<xref ref-type="bibr" rid="pntd.0005124.ref021">21</xref>], the costs in three different IDP camps were $1.28(I$4.88), $2.02(I$7.71) and $3.38(I$12.89). When prices were adjusted to I$, the costs of vaccination program increased substantially in all settings enhancing the variability across the sites. For example, the cost per unit of OCV delivery increased from US$ 4.70 to I$ 21.77 in Indonesia.</p>
<fig id="pntd.0005124.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0005124.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Vaccine delivery cost presented using three different methods (Method 1 = in USD vaccination year, Method 2 = in USD 2014, Method 3 = in I$ 2014).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0005124.g001" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec020" sec-type="conclusions">
<title>Discussion</title>
<p>When there is a cholera outbreak or an impending outbreak, there are three main intervention options besides management of cases and public awareness: Do nothing, water and sanitation improvement, and cholera vaccination. The cost of inaction against cholera outbreak could be substantial. One study reported that the drop in exports alone results in substantial trade loss accounting up to 1% of the countries’ GDP [<xref ref-type="bibr" rid="pntd.0005124.ref032">32</xref>]. Besides exports, the economic impact of a cholera outbreak includes tourism revenue loss, treatment expenditures and loss of income for those who are affected because they are unable to work. Water and sanitation improvement remains the choice of intervention for cholera and other diarrheal disease control, but requires large investments and takes long-term except personal level interventions such as provision of soap for hand wash and chlorine for water purification. The investments needed for upgrading water and sanitation system is difficult to measure and estimates widely vary. One study estimated that the access to regulated in-house piped water supply with quality monitoring and in-house sewerage connection with partial treatment of sewage for all would require a total investment of US$136.5 billion per year [<xref ref-type="bibr" rid="pntd.0005124.ref033">33</xref>]. Oral cholera vaccination is the interim intervention that is effective against cholera, at least in short-term. Accordingly, many OCV campaigns have taken place in different parts of the world, but the costs from those studies have been categorized and presented differently. A well-defined and limited set of basic categories may be more helpful to investigators, health authorities, policy makers, vaccination planners, and community stakeholders. The categories described herein allow for a clear, comparative understanding of vaccination campaign costs that can better guide decision-making.</p>
<p>The delivery costs of OCV through mass campaigns differed by country and even within the same country and same settings. The delivery cost of Shanchol in US$ 2014 varied from $1.14 in India to $3.05 in South Sudan per fully immunized person. The difference was higher in I$2014, ranging from I$4.08 in India to I$14.39 in South Sudan. Some of those differences could be because of the difference in provisions and activities during vaccination as discussed below, while other factors could be that the costs are collected and reported differently. However, the costs of OCV delivery in US$ 2014 in three different IDP settings in South Sudan ranged from $1.28 to $3.38 per fully immunized person. This cost difference could be partially attributed to the scale of vaccination, lowest costs of $1.28 was at IDP camp that vaccinated 38,200 people compared to the highest costs of $3.38 was at IDP camp that covered only 7,400 people. Once cost collection, categorization and presentations are standardized, the costs in US$ should help donors and financing bodies to decide the comparative resources required for vaccination in various settings. Whereas the costs in I$ will be helpful in comparing delivery costs across countries when in-country resources are used partially or completely as the case in many preemptive vaccinations in endemic settings.</p>
<p>Vaccine delivery costs were generally higher for Dukoral than Shanchol, with the exception of Uganda. The higher cost of Dukoral delivery could be partially because of its buffer requirement which complicates vaccine administration process requiring more materials and supplies. A higher proportion of delivery costs are constituted by materials and supply as reported in Tanzania (43.9%), Uganda (37.0%) and Mozambique (28.3%) where Dukoral was used. In Tanzania the material and supply costs were high because it included domestic vaccine storage and transport costs. The delivery costs in Uganda was lower because it did not include costs for program preparation (micro-planning, training, social mobilization &amp; sensitization and other preparation costs) and cold chain costs as the campaign used existing cold chain system for vaccine storage at operational headquarters (Entebbe) and did not use cold chain at field level (Adjumani). Also, vaccination coverage and acceptability survey, and AEFI data collections were not accounted for in the costs. In Uganda, Mozambique and Indonesia the vaccine was air-delivered to the site of vaccination due to difficulty in transport or security reasons or due to the fear of breaking the cold chain, which added substantially to the costs.</p>
<p>The costs of Shanchol delivery were highest in 2013 campaign in South Sudan compared to the other three countries that deployed the vaccine. In South Sudan 2013 campaign, items such as soap, cup and water was provided to Shanchol recipients, resulting in increased proportion of material and supply costs (42.1%). This was higher than other sites such as Bangladesh (13.6%) where these provisions were a part of a research activity and in Guinea (14.3%) where such provisions were part of outbreak preventive measures. Costs for Shanchol delivery were next highest in Guinea because of the transport costs where vaccination teams were mobile on car or boat. The proportion of staff salary and allowances as a part of vaccine administration cost was high in India (87.8%) and Bangladesh (62.7%) compared to Guinea (23.6%) and South Sudan (25.3%). The proportion was high in India because it included staff training costs and in Bangladesh it included costs for pre-vaccination census and intensive house to house mop-up vaccination.</p>
<p>The overall costs for administering ORC-Vax was relatively cheaper in Vietnam compared to other OCVs partly due to the fact that it was integrated into their routine immunization system [<xref ref-type="bibr" rid="pntd.0005124.ref031">31</xref>]. This suggests that the routine administration of OCV through existing immunization systems may reduce the vaccine delivery costs. However, the staff costs as a proportion of vaccine administration costs were relatively high (75.9%).</p>
<p>Vaccine procurement accounts for the highest proportion of the total vaccination program costs, the majority of which is due to the cost of the vaccine itself. Even if a country receives donated OCVs, international transportation of the donated vaccines to its borders as well as the clearance of the vaccines at the point of entry accounts for a sizable proportion of the costs. Besides scaling up vaccine supply through the entry of multiple competitive manufacturers [<xref ref-type="bibr" rid="pntd.0005124.ref034">34</xref>], a single dose vaccine strategy, if deployed, particularly in outbreak settings is likely to lower vaccine costs [<xref ref-type="bibr" rid="pntd.0005124.ref035">35</xref>]. The vaccine administration cost was the next highest because it involves intensive efforts to reach each individual to be vaccinated that needs lot of human resources, cold chain and materials such as vaccination card, soap, water and cups. As Shanchol does not need buffer, administering vaccine without provision of water and keeping OCV outside the cold chain could reduce some of these costs [<xref ref-type="bibr" rid="pntd.0005124.ref036">36</xref>].</p>
<p>There are several limitations in our analysis. First, the studies analyzed included only direct costs. The indirect costs—such as loss of income and transportation costs for those who spend time to visit a vaccination post [<xref ref-type="bibr" rid="pntd.0005124.ref037">37</xref>] are not accounted for. Adding these vaccine recipient costs would be valuable for a better understanding of the total costs of vaccination and help in developing plans to reduce vaccine recipient’s costs which may improve vaccine acceptance [<xref ref-type="bibr" rid="pntd.0005124.ref038">38</xref>]. Two of the Shanchol costing studies later published OCV delivery costs under societal perspective [<xref ref-type="bibr" rid="pntd.0005124.ref037">37</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref039">39</xref>]. Second, several of the studies included in our analysis organized the costs using their own methods and costing categories, which made it difficult to reorganize the costs for the purposes of our analysis [<xref ref-type="bibr" rid="pntd.0005124.ref012">12</xref>–<xref ref-type="bibr" rid="pntd.0005124.ref014">14</xref>,<xref ref-type="bibr" rid="pntd.0005124.ref020">20</xref>]. This insufficient and unclear information may have resulted in some misclassification of cost categories. Third, we only could include financial costs, not economic costs as most studies presented financial costs. Inclusion of economic costs in future studies is important to understand all the costs-involved in conducting OCV campaigns and also to conduct cost-effectiveness analysis. Fourth, the presentation of costs in selected papers did not allow us to differentiate between fixed and variable costs. The fixed costs will not be affected by a larger OCV introduction while, the variable costs per unit will be further reduced by scaling up the program. It is important to identify and list fixed and variable costs in future costing studies. Fifth, the scope of this work was confined to vaccine delivery costs and it does not include value for money measures such as cost-effectiveness analysis. The reviews on health economic evaluations around OCV delivery will be useful in informed decision making. Finally, availability of unpublished data from two sites (Malawi and Ethiopia) would have improved the cost estimation.</p>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Conclusion</title>
<p>Understanding the costs of cholera vaccination campaigns is of paramount importance in the economic evaluation as well as in planning future vaccination programs. Currently, there is limited OCV delivery cost data, collected inconsistently and reported capriciously limiting the comparability of costs across settings. Categorizing the costs into easily differentiable categories is useful to the planning process and comparison between campaigns. We recommend that future OCV costing studies include both financial and economic costs and use the cost categories defined in this study for clearer collation, analysis, and comparison of campaign costs.</p>
</sec>
<sec id="sec022">
<title>Supporting Information</title>
<supplementary-material id="pntd.0005124.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pntd.0005124.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>PRISMA checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0005124.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pntd.0005124.s002" xlink:type="simple">
<label>S1 Flowchart</label>
<caption>
<title>PRISMA flowchart.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Iza Ciglenecki of MSF for sharing the report on Maban Country for OCV mass vaccination.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0005124.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>Publication WHO</collab> (<year>2010</year>) <article-title>Cholera vaccines: WHO position paper-Recommendations</article-title>. <source>Vaccine</source> <volume>28</volume>: <fpage>4687</fpage>–<lpage>4688</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2010.05.008" xlink:type="simple">10.1016/j.vaccine.2010.05.008</ext-link></comment> <object-id pub-id-type="pmid">20483196</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zuckerman</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Rombo</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Fisch</surname> <given-names>A</given-names></name> (<year>2007</year>) <article-title>The true burden and risk of cholera: implications for prevention and control</article-title>. <source>Lancet Infect Dis</source> <volume>7</volume>: <fpage>521</fpage>–<lpage>530</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(07)70138-X" xlink:type="simple">10.1016/S1473-3099(07)70138-X</ext-link></comment> <object-id pub-id-type="pmid">17584531</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wierzba</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Kar</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Mogasale</surname> <given-names>VV</given-names></name>, <name name-style="western"><surname>Kerketta</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>YA</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India</article-title>. <source>Vaccine</source> <volume>33</volume>: <fpage>2463</fpage>–<lpage>2469</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2015.03.073" xlink:type="simple">10.1016/j.vaccine.2015.03.073</ext-link></comment> <object-id pub-id-type="pmid">25850019</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Severe</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Rouzier</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Anglade</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Bertil</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Joseph</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up</article-title>. <source>Am J Trop Med Hyg</source> <volume>94</volume>: <fpage>1136</fpage>–<lpage>1142</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4269/ajtmh.15-0700" xlink:type="simple">10.4269/ajtmh.15-0700</ext-link></comment> <object-id pub-id-type="pmid">26928838</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luquero</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Grout</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ciglenecki</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Sakoba</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Traore</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Use of Vibrio cholerae vaccine in an outbreak in Guinea</article-title>. <source>N Engl J Med</source> <volume>370</volume>: <fpage>2111</fpage>–<lpage>2120</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1312680" xlink:type="simple">10.1056/NEJMoa1312680</ext-link></comment> <object-id pub-id-type="pmid">24869721</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clemens</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sur</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Nair</surname> <given-names>GB</given-names></name>, <name name-style="western"><surname>Holmgren</surname> <given-names>J</given-names></name> (<year>2011</year>) <article-title>New-generation vaccines against cholera</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <volume>8</volume>: <fpage>701</fpage>–<lpage>710</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrgastro.2011.174" xlink:type="simple">10.1038/nrgastro.2011.174</ext-link></comment> <object-id pub-id-type="pmid">22064524</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hill</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Ford</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lalloo</surname> <given-names>DG</given-names></name> (<year>2006</year>) <article-title>Oral cholera vaccines: use in clinical practice</article-title>. <source>Lancet Infect Dis</source> <volume>6</volume>: <fpage>361</fpage>–<lpage>373</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(06)70494-7" xlink:type="simple">10.1016/S1473-3099(06)70494-7</ext-link></comment> <object-id pub-id-type="pmid">16728322</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anh</surname> <given-names>DD</given-names></name>, <name name-style="western"><surname>Lopez</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Tran</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Cuong</surname> <given-names>NV</given-names></name>, <name name-style="western"><surname>Thiem</surname> <given-names>VD</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Oral cholera vaccine development and use in Vietnam</article-title>. <source>PLoS Med</source> <volume>11</volume>: <fpage>e1001712</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001712" xlink:type="simple">10.1371/journal.pmed.1001712</ext-link></comment> <object-id pub-id-type="pmid">25180511</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yen</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hyde</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tam</surname> <given-names>JS</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>The development of global vaccine stockpiles</article-title>. <source>Lancet Infect Dis</source> <volume>15</volume>: <fpage>340</fpage>–<lpage>347</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(14)70999-5" xlink:type="simple">10.1016/S1473-3099(14)70999-5</ext-link></comment> <object-id pub-id-type="pmid">25661473</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nelson</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mogasale</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bari</surname> <given-names>TI</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>JD</given-names></name> (<year>2014</year>) <article-title>Considerations around the introduction of a cholera vaccine in Bangladesh</article-title>. <source>Vaccine</source> <volume>32</volume>: <fpage>7033</fpage>–<lpage>7036</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2014.05.028" xlink:type="simple">10.1016/j.vaccine.2014.05.028</ext-link></comment> <object-id pub-id-type="pmid">24856784</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lopez</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Bellos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Deen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Post-licensure deployment of oral cholera vaccines: a systematic review</article-title>. <source>Bull World Health Organ</source> <volume>92</volume>: <fpage>881</fpage>–<lpage>893</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2471/BLT.14.139949" xlink:type="simple">10.2471/BLT.14.139949</ext-link></comment> <object-id pub-id-type="pmid">25552772</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Legros</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Paquet</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Perea</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Marty</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Mugisha</surname> <given-names>NK</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Mass vaccination with a two-dose oral cholera vaccine in a refugee camp</article-title>. <source>Bull World Health Organ</source> <volume>77</volume>: <fpage>837</fpage>–<lpage>842</lpage>. <object-id pub-id-type="pmid">10593032</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cavailler</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lucas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Perroud</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>McChesney</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ampuero</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique</article-title>. <source>Vaccine</source> <volume>24</volume>: <fpage>4890</fpage>–<lpage>4895</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2005.10.006" xlink:type="simple">10.1016/j.vaccine.2005.10.006</ext-link></comment> <object-id pub-id-type="pmid">16298025</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaetti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Weiss</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Chaignat</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Khatib</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar</article-title>. <source>PLoS Negl Trop Dis</source> <volume>6</volume>: <fpage>e1844</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0001844" xlink:type="simple">10.1371/journal.pntd.0001844</ext-link></comment> <object-id pub-id-type="pmid">23056660</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kar</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Patnaik</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Kerketta</surname> <given-names>AS</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model</article-title>. <source>PLoS Negl Trop Dis</source> <volume>8</volume>: <fpage>e2629</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002629" xlink:type="simple">10.1371/journal.pntd.0002629</ext-link></comment> <object-id pub-id-type="pmid">24516675</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khan</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Saha</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chowdhury</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Uddin</surname> <given-names>MJ</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh</article-title>. <source>Vaccine</source> <volume>31</volume>: <fpage>6058</fpage>–<lpage>6064</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2013.10.021" xlink:type="simple">10.1016/j.vaccine.2013.10.021</ext-link></comment> <object-id pub-id-type="pmid">24161413</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ciglenecki</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Sakoba</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Luquero</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Heile</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Itama</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea</article-title>. <source>PLoS Med</source> <volume>10</volume>: <fpage>e1001512</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001512" xlink:type="simple">10.1371/journal.pmed.1001512</ext-link></comment> <object-id pub-id-type="pmid">24058301</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref018"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chiwanda M (2015) 160 000 people targeted with oral cholera vaccine in Nsanje. International Vaccine Institute.News releases and statements no. 141.</mixed-citation></ref>
<ref id="pntd.0005124.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Phares</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Date</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Travers</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Deglise</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wongjindanon</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand</article-title>. <source>Vaccine</source> <volume>34</volume>: <fpage>128</fpage>–<lpage>133</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2015.10.112" xlink:type="simple">10.1016/j.vaccine.2015.10.112</ext-link></comment> <object-id pub-id-type="pmid">26549363</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref020"><label>20</label><mixed-citation publication-type="book" xlink:type="simple">(<year>2006</year>) <source>Use of the two-dose oral cholera vaccine in the context of a major natural disaster: report of a mass vaccination campaign in Aceh Province, Indonesia, 2005</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref>
<ref id="pntd.0005124.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple">(<year>2014</year>) <article-title>Oral cholera vaccine campaign among internally displaced persons in South Sudan</article-title>. <source>Wkly Epidemiol Rec</source> <volume>89</volume>: <fpage>214</fpage>–<lpage>220</lpage>. <object-id pub-id-type="pmid">24864347</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Levin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Levin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Tsu</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Hutubessy</surname> <given-names>R</given-names></name> (<year>2014</year>) <article-title>Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries</article-title>. <source>PLoS One</source> <volume>9</volume>: <fpage>e101114</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0101114" xlink:type="simple">10.1371/journal.pone.0101114</ext-link></comment> <object-id pub-id-type="pmid">24968002</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref023"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">(2015) The World Bank. New Country Classifications.</mixed-citation></ref>
<ref id="pntd.0005124.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Group</surname> <given-names>TP</given-names></name> (<year>2009</year>) <article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title>. <source>PLoS Medicine</source> <volume>6</volume>: <fpage>e1000097</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000097" xlink:type="simple">10.1371/journal.pmed.1000097</ext-link></comment> <object-id pub-id-type="pmid">19621072</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhattacharya</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Sur</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kanungo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>YA</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Infect Dis</source> <volume>13</volume>: <fpage>1050</fpage>–<lpage>1056</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(13)70273-1" xlink:type="simple">10.1016/S1473-3099(13)70273-1</ext-link></comment> <object-id pub-id-type="pmid">24140390</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>You</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kanungo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Manna</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Risk map of cholera infection for vaccine deployment: the eastern Kolkata case</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e71173</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0071173" xlink:type="simple">10.1371/journal.pone.0071173</ext-link></comment> <object-id pub-id-type="pmid">23936491</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref027"><label>27</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Gray</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Clarke</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Wolstenholme</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Wordsworth</surname> <given-names>S</given-names></name> (<year>2011</year>) <source>Applied methods of cost-effectiveness analysis in health care</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>.</mixed-citation></ref>
<ref id="pntd.0005124.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ali</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sur</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Kanungo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India</article-title>. <source>Clin Infect Dis</source> <volume>56</volume>: <fpage>1123</fpage>–<lpage>1131</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cit009" xlink:type="simple">10.1093/cid/cit009</ext-link></comment> <object-id pub-id-type="pmid">23362293</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref029"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">MSF (2012) Mass Oral Cholera Vaccination Campaign (OCV) in Maban County in the refugee camps and host population in the direct surroundings of the camps. Medecins sans Frontieres Holland.</mixed-citation></ref>
<ref id="pntd.0005124.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chaignat</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Monti</surname> <given-names>V</given-names></name> (<year>2007</year>) <article-title>Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO</article-title>. <source>J Health Popul Nutr</source> <volume>25</volume>: <fpage>244</fpage>–<lpage>261</lpage>. <object-id pub-id-type="pmid">17985828</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vu</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Hossain</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Rao</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam</article-title>. <source>J Health Popul Nutr</source> <volume>21</volume>: <fpage>304</fpage>–<lpage>308</lpage>. <object-id pub-id-type="pmid">15043004</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimball</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Taneda</surname> <given-names>K</given-names></name> (<year>2005</year>) <article-title>An evidence base for International Health Regulations: quantitative measurement of the impacts of epidemic disease on international trade</article-title>. <source>Rev Sci Tech</source> <volume>24</volume>: <fpage>825</fpage>–<lpage>832</lpage>. <object-id pub-id-type="pmid">16642753</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref033"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2004) Costs and benefits of water and sanitation improvements at the global level (Evaluation of the).</mixed-citation></ref>
<ref id="pntd.0005124.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Desai</surname> <given-names>SN</given-names></name>, <name name-style="western"><surname>Pezzoli</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rodriguez</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>A second affordable oral cholera vaccine: implications for the global vaccine stockpile</article-title>. <source>Lancet Glob Health</source> <volume>4</volume>: <fpage>e223</fpage>–<lpage>224</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S2214-109X(16)00037-1" xlink:type="simple">10.1016/S2214-109X(16)00037-1</ext-link></comment> <object-id pub-id-type="pmid">27013303</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Azman</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Luquero</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Ciglenecki</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Grais</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Sack</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study</article-title>. <source>PLoS Med</source> <volume>12</volume>: <fpage>e1001867</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001867" xlink:type="simple">10.1371/journal.pmed.1001867</ext-link></comment> <object-id pub-id-type="pmid">26305226</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saha</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Salma</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Jahan</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname> <given-names>TR</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>The oral cholera vaccine Shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants</article-title>. <source>Vaccine</source> <volume>34</volume>: <fpage>1551</fpage>–<lpage>1558</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2016.02.020" xlink:type="simple">10.1016/j.vaccine.2016.02.020</ext-link></comment> <object-id pub-id-type="pmid">26896684</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mogasale</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Kar</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Mogasale</surname> <given-names>VV</given-names></name>, <name name-style="western"><surname>Kerketta</surname> <given-names>AS</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India</article-title>. <source>PLoS Negl Trop Dis</source> <volume>9</volume>: <fpage>e0004072</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0004072" xlink:type="simple">10.1371/journal.pntd.0004072</ext-link></comment> <object-id pub-id-type="pmid">26352143</object-id></mixed-citation></ref>
<ref id="pntd.0005124.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jeuland</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lucas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Whittington</surname> <given-names>D</given-names></name> (<year>2010</year>) <article-title>Estimating the private benefits of vaccination against cholera in Beira, Mozambique: A travel cost approach</article-title>. <source>J Dev Econ</source> <volume>91</volume>: <fpage>310</fpage>–<lpage>322</lpage>.</mixed-citation></ref>
<ref id="pntd.0005124.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sarker</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Islam</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Saha</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chowdhury</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh</article-title>. <source>Vaccine</source> <volume>33</volume>: <fpage>4916</fpage>–<lpage>4921</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2015.07.042" xlink:type="simple">10.1016/j.vaccine.2015.07.042</ext-link></comment> <object-id pub-id-type="pmid">26232545</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>